#1 Clinical Trials Search in Europe

Cabazitaxel

Cabazitaxel is an innovative chemotherapy drug being studied in clinical trials for its potential to treat various types of cancer. This article explores the use of cabazitaxel in clinical trials for different cancer types, including prostate, breast, brain, and gastrointestinal cancers. We’ll discuss its mechanism of action, potential benefits, and ongoing research to better understand its efficacy and safety profile.

Table of Contents

What is Cabazitaxel?

Cabazitaxel is a novel cancer chemotherapy drug that belongs to the taxane class of medications. It is also known by its brand name Jevtana[1]. Other names for this drug include XRP6258 and RPR116258A[2]. Cabazitaxel is a semi-synthetic taxoid, which means it is derived from natural sources but has been chemically modified to enhance its effectiveness[1].

How Cabazitaxel Works

Cabazitaxel works by binding to and stabilizing tubulin structures in cells. Tubulin is a protein that forms microtubules, which are essential for cell division. By stabilizing these structures, Cabazitaxel prevents the breakdown of microtubules, which in turn inhibits cell division and tumor cell proliferation[1].

What makes Cabazitaxel unique among taxanes is its low affinity for a protein called P-glycoprotein. This protein is a drug efflux pump, which means it can remove certain drugs from cells. Many cancer cells produce high levels of P-glycoprotein, which can lead to resistance to traditional taxane drugs. Cabazitaxel’s low affinity for P-glycoprotein may allow it to overcome this resistance mechanism[1].

Conditions Treated with Cabazitaxel

Cabazitaxel is primarily used to treat several types of cancer:

  • Prostate Cancer: Cabazitaxel is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously been treated with a docetaxel-containing regimen[3]. Metastatic means the cancer has spread to other parts of the body, and castration-resistant means the cancer continues to grow even when the level of testosterone is reduced to very low levels.
  • Urothelial Carcinoma: This is a type of bladder cancer. Cabazitaxel is being studied as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma who have progressed after platinum-based chemotherapy[4].
  • Head and Neck Cancer: Research is ongoing to evaluate the effectiveness of Cabazitaxel in treating recurrent or metastatic head and neck cancer in patients who have not responded to other treatments[5].
  • Gastroesophageal Cancer: Studies are being conducted to assess the effectiveness of Cabazitaxel in patients with advanced gastroesophageal cancer who have progressed after at least one line of chemotherapy[1].

How Cabazitaxel is Administered

Cabazitaxel is typically administered as an intravenous (IV) infusion. The standard dose is usually 25 mg/m² (milligrams per square meter of body surface area) given over one hour every 21 days[4]. However, the exact dosage and schedule may vary depending on the specific condition being treated and the patient’s individual factors.

Before receiving Cabazitaxel, patients are usually given premedications to help prevent allergic reactions and other side effects. These may include:

  • Antihistamines (such as dexchlorpheniramine or diphenhydramine)
  • Corticosteroids (such as dexamethasone)
  • H2 antagonists (such as ranitidine)
  • Anti-nausea medications (such as ondansetron)[6]

In some cases, Cabazitaxel may be given along with other medications. For example, in prostate cancer treatment, it is often combined with prednisone, a steroid medication that helps reduce inflammation and other symptoms[3].

Side Effects and Safety Considerations

Like all chemotherapy drugs, Cabazitaxel can cause side effects. Some of the most common and significant side effects include:

  • Neutropenia: This is a decrease in white blood cells called neutrophils, which can increase the risk of infections. It is one of the most common and serious side effects of Cabazitaxel[6].
  • Febrile Neutropenia: This is a condition where a patient with neutropenia develops a fever, indicating a possible infection[7].
  • Diarrhea: This can be severe in some cases and may require treatment[7].
  • Fatigue: Many patients experience tiredness or weakness during treatment.
  • Nausea and Vomiting: These are common side effects of many chemotherapy drugs, including Cabazitaxel.

To help manage these side effects, especially neutropenia, doctors may prescribe medications called granulocyte-colony stimulating factors (G-CSF). These drugs help stimulate the production of white blood cells[6].

Ongoing Research and Future Prospects

Researchers continue to study Cabazitaxel to find new ways to use it effectively and safely. Some areas of ongoing research include:

  • Neoadjuvant Treatment: Studies are looking at using Cabazitaxel before surgery (neoadjuvant therapy) in patients with high-risk prostate cancer[2].
  • Combination Therapies: Researchers are investigating how Cabazitaxel works when combined with other treatments, such as hormonal therapy for prostate cancer[2].
  • Biomarkers: Scientists are trying to identify biological markers that could help predict which patients are most likely to benefit from Cabazitaxel treatment[8].
  • Quality of Life: Studies are assessing how Cabazitaxel treatment affects patients’ quality of life compared to other treatments[2].

As research continues, our understanding of how to use Cabazitaxel most effectively will likely improve, potentially leading to better outcomes for patients with various types of cancer.

Aspect Details
Cancer Types Studied Prostate cancer, breast cancer, brain metastases, gastroesophageal cancer, liposarcoma
Administration Method Intravenous infusion, typically every 21 days
Common Dosages 20-25 mg/m², with some trials exploring alternative schedules
Key Advantages Potential to overcome resistance to other taxanes, ability to cross blood-brain barrier
Primary Outcomes Measured Progression-free survival, overall survival, objective response rate, safety profile
Combination Therapies Studied with hormonal treatments, radiotherapy, and as part of multi-drug regimens
Patient Populations Often patients with advanced or metastatic cancers who have progressed after prior treatments

FAQ

  • What is cabazitaxel and how does it work? Cabazitaxel is a chemotherapy drug that belongs to the taxane family. It works by interfering with cell division and growth, specifically by binding to and stabilizing tubulin structures in cancer cells. This action inhibits the growth and spread of cancer cells.
  • Which types of cancer is cabazitaxel being studied for? Clinical trials are investigating cabazitaxel for various cancer types, including prostate cancer, breast cancer, brain metastases, gastrointestinal cancers (such as gastroesophageal cancer), and liposarcoma.
  • What are the potential advantages of cabazitaxel over other chemotherapy drugs? Cabazitaxel has shown potential advantages over other chemotherapy drugs, including its ability to overcome resistance to traditional taxanes like docetaxel and paclitaxel. It also has the ability to cross the blood-brain barrier, making it a promising option for treating brain metastases.
  • How is cabazitaxel typically administered in clinical trials? In most clinical trials, cabazitaxel is administered intravenously (by IV) every 21 days, with doses ranging from 20 to 25 mg/m². Some trials are also exploring different dosing schedules, such as weekly administration, to optimize efficacy and minimize side effects.
  • What are the main goals of cabazitaxel clinical trials? The main goals of cabazitaxel clinical trials include determining its efficacy in treating various cancer types, assessing its safety profile and potential side effects, identifying the optimal dosing schedule, and comparing its performance to other standard treatments or in combination with other therapies.

Ongoing Clinical Trials on Cabazitaxel

  • Study of Nivolumab, Ipilimumab, or Cabazitaxel for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Cabazitaxel: A chemotherapy drug belonging to the taxane family, designed to interfere with cancer cell division and growth. It has shown potential in treating various types of cancer, including those resistant to other taxane drugs.
  • Taxane: A class of chemotherapy drugs that work by disrupting cell division. They are commonly used to treat various types of cancer, including breast, ovarian, and lung cancers.
  • Metastatic: Referring to cancer that has spread from its original site to other parts of the body.
  • Neoadjuvant treatment: Treatment given before the main treatment, usually to shrink a tumor before surgery or radiation therapy.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Blood-brain barrier: A protective barrier that prevents many substances, including some drugs, from entering the brain from the bloodstream.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT01365130
  2. https://clinicaltrials.gov/study/NCT04622761
  3. https://clinicaltrials.gov/study/NCT01254279
  4. https://clinicaltrials.gov/study/NCT01600339
  5. https://clinicaltrials.gov/study/NCT01620242
  6. https://clinicaltrials.gov/study/NCT02441894
  7. https://clinicaltrials.gov/study/NCT01649635
  8. https://clinicaltrials.gov/study/NCT01718353